Drug targets and predictive biomarkers in the management of metastatic melanoma
Jaykumar Thumar, Eva Giesen, Harriet M KlugerYale Cancer Center, Yale School of Medicine, New Haven, CT, USAAbstract: Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-09-01
|
| Series: | Pharmacogenomics and Personalized Medicine |
| Online Access: | http://www.dovepress.com/drug-targets-and-predictive-biomarkers-in-the-management-of-metastatic-a11148 |
| _version_ | 1811261578132062208 |
|---|---|
| author | Thumar J Giesen E Kluger HM |
| author_facet | Thumar J Giesen E Kluger HM |
| author_sort | Thumar J |
| collection | DOAJ |
| description | Jaykumar Thumar, Eva Giesen, Harriet M KlugerYale Cancer Center, Yale School of Medicine, New Haven, CT, USAAbstract: Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic melanoma were limited. The approval of ipilimumab (an anti-CTLA-4 antibody) and vemurafenib (mutant B-RAFV600E kinase inhibitor) by the Federal Drug Administration has led to a new era in melanoma treatment, and additional promising drugs and drug combinations are currently being investigated. As the choices of treatment for melanoma have expanded, the need to identify predictive biomarkers to tailor treatment strategies to individual tumor or immune system characteristics has become necessary. Such strategies have the potential of maximizing antitumor effect while minimizing toxicity and improving clinical benefit. In this article, we review the currently approved targeted therapies in melanoma and discuss the future of personalized therapy for this disease.Keywords: vemurafenib, mutations, inhibitors, tumors |
| first_indexed | 2024-04-12T19:06:57Z |
| format | Article |
| id | doaj.art-c7b3d1f1d78d407891cb13f06d3ca967 |
| institution | Directory Open Access Journal |
| issn | 1178-7066 |
| language | English |
| last_indexed | 2024-04-12T19:06:57Z |
| publishDate | 2012-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Pharmacogenomics and Personalized Medicine |
| spelling | doaj.art-c7b3d1f1d78d407891cb13f06d3ca9672022-12-22T03:20:00ZengDove Medical PressPharmacogenomics and Personalized Medicine1178-70662012-09-012012default139148Drug targets and predictive biomarkers in the management of metastatic melanomaThumar JGiesen EKluger HMJaykumar Thumar, Eva Giesen, Harriet M KlugerYale Cancer Center, Yale School of Medicine, New Haven, CT, USAAbstract: Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic melanoma were limited. The approval of ipilimumab (an anti-CTLA-4 antibody) and vemurafenib (mutant B-RAFV600E kinase inhibitor) by the Federal Drug Administration has led to a new era in melanoma treatment, and additional promising drugs and drug combinations are currently being investigated. As the choices of treatment for melanoma have expanded, the need to identify predictive biomarkers to tailor treatment strategies to individual tumor or immune system characteristics has become necessary. Such strategies have the potential of maximizing antitumor effect while minimizing toxicity and improving clinical benefit. In this article, we review the currently approved targeted therapies in melanoma and discuss the future of personalized therapy for this disease.Keywords: vemurafenib, mutations, inhibitors, tumorshttp://www.dovepress.com/drug-targets-and-predictive-biomarkers-in-the-management-of-metastatic-a11148 |
| spellingShingle | Thumar J Giesen E Kluger HM Drug targets and predictive biomarkers in the management of metastatic melanoma Pharmacogenomics and Personalized Medicine |
| title | Drug targets and predictive biomarkers in the management of metastatic melanoma |
| title_full | Drug targets and predictive biomarkers in the management of metastatic melanoma |
| title_fullStr | Drug targets and predictive biomarkers in the management of metastatic melanoma |
| title_full_unstemmed | Drug targets and predictive biomarkers in the management of metastatic melanoma |
| title_short | Drug targets and predictive biomarkers in the management of metastatic melanoma |
| title_sort | drug targets and predictive biomarkers in the management of metastatic melanoma |
| url | http://www.dovepress.com/drug-targets-and-predictive-biomarkers-in-the-management-of-metastatic-a11148 |
| work_keys_str_mv | AT thumarj drugtargetsandpredictivebiomarkersinthemanagementofmetastaticmelanoma AT giesene drugtargetsandpredictivebiomarkersinthemanagementofmetastaticmelanoma AT klugerhm drugtargetsandpredictivebiomarkersinthemanagementofmetastaticmelanoma |